{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:33:56Z","timestamp":1792103636868,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"vor","delay-in-days":381,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","onlinejacc.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.jacc.2018.04.060","type":"journal-article","created":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T14:07:53Z","timestamp":1531145273000},"page":"287-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"title":["Lipoprotein(a) and Cardiovascular Risk Prediction Among Women"],"prefix":"10.1016","volume":"72","author":[{"given":"Nancy R.","family":"Cook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"Ridker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2018.04.060_bib1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.04.060_bib2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study","volume":"64","author":"Willeit","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.04.060_bib3","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.04.060_bib4","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.04.060_bib5","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1161\/ATVBAHA.114.303462","article-title":"A\u00a0common LPA null allele associates with lower lipoprotein(a) levels and coronary artery disease risk","volume":"34","author":"Kyriakou","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2018.04.060_bib6","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A\u00a0test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.04.060_bib7","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2016.01.005","article-title":"Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a)","volume":"10","author":"Yeang","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2018.04.060_bib8","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/ATVBAHA.113.302479","article-title":"Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease","volume":"33","author":"Nestel","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2018.04.060_bib9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.04.060_bib10","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.04.060_bib11","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.04.060_bib12","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/jama.296.11.1363","article-title":"Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women","volume":"296","author":"Suk Danik","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.04.060_bib13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jacc.2008.04.009","article-title":"Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events","volume":"52","author":"Suk Danik","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.04.060_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/152460900318911","article-title":"Baseline characteristics of participants in the Women's Health Study","volume":"9","author":"Rexrode","year":"2000","journal-title":"J\u00a0Womens Health Gend Based Med"},{"key":"10.1016\/j.jacc.2018.04.060_bib15","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A\u00a0randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.04.060_bib16","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jama.297.6.611","article-title":"Development and validation of improved algorithms for the assessment of global cardiovascular risk in women","volume":"297","author":"Ridker","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.04.060_bib17","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.111.075929","article-title":"Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative","volume":"125","author":"Cook","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.04.060_bib18","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.04.060_bib19","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.04.060_bib20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","article-title":"Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy","volume":"203","author":"Chasman","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2018.04.060_bib21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/sim.2929","article-title":"Evaluating the added predictive ability of a new biomarker: from area under the ROC curve to reclassification and beyond","volume":"27","author":"Pencina","year":"2008","journal-title":"Stat Med"},{"key":"10.1016\/j.jacc.2018.04.060_bib22","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1161\/CIRCULATIONAHA.106.672402","article-title":"Use and misuse of the receiver operating characteristic curve in risk prediction","volume":"115","author":"Cook","year":"2007","journal-title":"Circ"},{"key":"10.1016\/j.jacc.2018.04.060_bib23","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/0003-4819-150-11-200906020-00007","article-title":"Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures","volume":"150","author":"Cook","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2018.04.060_bib24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/sim.4026","article-title":"Several methods to assess improvement in risk prediction models: extension to survival analysis","volume":"30","author":"Chambless","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.jacc.2018.04.060_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/sim.4085","article-title":"Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers","volume":"30","author":"Pencina","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.jacc.2018.04.060_bib26","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/01621459.1952.10483446","article-title":"A\u00a0generalization of sampling without replacement from a finite universe","volume":"47","author":"Horvitz","year":"1952","journal-title":"J\u00a0Amer Statist Assoc"},{"key":"10.1016\/j.jacc.2018.04.060_bib27","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.2307\/2533444","article-title":"Robust variance estimation for the case-cohort design","volume":"50","author":"Barlow","year":"1994","journal-title":"Biom"},{"key":"10.1016\/j.jacc.2018.04.060_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1023\/A:1009661900674","article-title":"Exposure stratified case-cohort designs","volume":"6","author":"Borgan","year":"2000","journal-title":"Lifetime Data Analy"},{"key":"10.1016\/j.jacc.2018.04.060_bib29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1023\/A:1009691327335","article-title":"Computing the Cox model for case cohort designs","volume":"5","author":"Therneau","year":"1999","journal-title":"Lifetime Data Analy"},{"key":"10.1016\/j.jacc.2018.04.060_bib30","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0895-4356(99)00102-X","article-title":"Analysis of case-cohort designs","volume":"52","author":"Barlow","year":"1999","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jacc.2018.04.060_bib31","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1016\/j.csda.2006.12.028","article-title":"Computational methods for case-cohort studies","volume":"51","author":"Langholz","year":"2007","journal-title":"Comp Stats Data Analysis"},{"key":"10.1016\/j.jacc.2018.04.060_bib32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/aje\/kws207","article-title":"Interpreting incremental value of markers added to risk prediction models","volume":"176","author":"Pencina","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacc.2018.04.060_bib33","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.jacc.2017.01.017","article-title":"Lipoprotein(a) improves cardiovascular risk prediction based on established risk algorithms","volume":"69","author":"Verbeek","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.04.060_bib34","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/0272989X12461856","article-title":"A\u00a0bias-corrected net reclassification improvement for clinical subgroups","volume":"33","author":"Paynter","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jacc.2018.04.060_bib35","doi-asserted-by":"crossref","first-page":"i4450","DOI":"10.1136\/bmj.i4450","article-title":"Adding tests to risk based guidelines: evaluating improvements in prediction for an intermediate risk group","volume":"354","author":"Paynter","year":"2016","journal-title":"BMJ"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109718348162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109718348162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T20:53:29Z","timestamp":1563310409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109718348162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0735109718348162"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2018.04.060","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a) and Cardiovascular Risk Prediction Among Women","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2018.04.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}